Onconetix, Inc.
No SEC Form 4 filings for $ONCO in the last 30 days.
See all $ONCO insider activity →Oncopeptides AB (publ) will host a webcast on Oct 12 after reporting positive interim data for OP-701, showing its PDC platform penetrated the blood-brain barrier in glioblastoma patients. The company did not provide full efficacy or safety data.
Oncopeptides reported initial data from its INSULA WoO study, showing blood-brain-barrier penetration and good tolerability in the first three patients with glioblastoma. The company is recruiting up to 10 patients. This is early-stage data, not efficacy results.
Onconetix Inc. (NASDAQ: ONCO) stock rose 14.58% on news of its AI robotics deal with Realbotix, backed by SRX Global. The company's stock has been volatile, trading between $0.64 and $1.40 recently. ONCO has small revenue ($0.8M) and steep losses but holds $5.9M in cash. The Realbotix acquisition aims to pivot into AI and defense sectors, with a pilot project underway. ONCO provided $2.5M in bridge financing, with a 12% interest penalty if the deal fails.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ONCO (Onconetix, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent ONCO coverage spans technology, mergers & acquisitions and corporate actions.
Positive early‑stage data may boost investor sentiment.
Early proof‑of‑delivery could lift sentiment and attract funding.
The deal provides a catalyst for upside but carries execution risk.
Acquisition adds AI robotics capability, diversifying ONCO's portfolio.
The deal adds AI‑robotics exposure and potential upside if integration succeeds, but introduces dilution and financing risk.
AlphAI scores every news story that mentions ONCO with an AI model for sentiment and relevance, and aggregates insider trades from Onconetix, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Oncopeptides AB (publ) will host a webcast on Oct 12 after reporting positive interim data for OP-701, showing its PDC platform penetrated the blood-brain barrier in glioblastoma patients. The company did not provide full efficacy or safety data.
1 min readOncopeptides reported initial data from its INSULA WoO study, showing blood-brain-barrier penetration and good tolerability in the first three patients with glioblastoma. The company is recruiting up to 10 patients. This is early-stage data, not efficacy results.
1 min readOnconetix Inc. (NASDAQ: ONCO) stock rose 14.58% on news of its AI robotics deal with Realbotix, backed by SRX Global. The company's stock has been volatile, trading between $0.64 and $1.40 recently. ONCO has small revenue ($0.8M) and steep losses but holds $5.9M in cash. The Realbotix acquisition aims to pivot into AI and defense sectors, with a pilot project underway. ONCO provided $2.5M in bridge financing, with a 12% interest penalty if the deal fails.
2 min readADARx (ADRX) priced its IPO at $17/share, raising $446.3M, with AbbVie investing $100M. CNSY (CNSY) secured reimbursement with Blue Cross Blue Shield. JAGX (JAGX) completed a reverse stock split. AGL (AGL) expanded its partnership with Springfield Clinic. ONCO (ONCO) agreed to acquire Realbotix. All stocks traded higher.
2 min readOnconetix Inc. (NASDAQ: ONCO) shares rose 19.69% after positive oncology trial results and an AI robotics deal. The company is acquiring Realbotix LLC, an AI-powered humanoid robot developer, in an all-stock transaction. ONCO provided $2.5M in bridge financing, with potential for $5M total. The company has minimal revenue ($0.82M) and negative net margins, but low debt and a high current ratio. Traders are watching the Realbotix pivot and potential Nasdaq uplisting.
2 min readOnco-Innovations (ONCO, ONNVF) and Redwood AI (AIRX, RDWCF) received a Digital Health Innovation Fund grant for their AI-driven oncology platform, SynoGraph. The grant covers up to 25% of the $3.5M project budget. The companies will collaborate with academic partners to advance the platform using federated learning and causal AI.
1 min readOncopeptides AB (ONCO) announced that the CHMP recommended expanding Pepaxti's indication to third-line treatment for multiple myeloma, potentially doubling its addressable patient population. The European Commission will decide within 30-60 days. The company expects this to unlock commercial opportunities and support cash-flow positivity in 2027.
2 min readOnconetix, Inc. (ONCO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Filed by Onconetix, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) under the Securities Exchange Act of 1934 Subject Company: Onconetix, Inc. Commission File No.: 001-41294 Date: September 14,2026 Onconetix Provi
2 min readOnconetix, Inc. (ONCO) announced that Realbotix LLC, its pending acquisition target, has launched a pilot program with a European telecom firm to deploy AI-powered humanoid robots in live events. The pilot will evaluate robots' ability to present, host, and engage with audiences. Onconetix aims to complete the acquisition in the second half of 2026, subject to approvals. ONCO stock is currently at $0.70, up 3.86%.
1 min readOnconetix, Inc. (ONCO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement PIPE Financing On July 28, 2026, Onconetix, Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with an accredited investor (the “ PIPE Investor ”
6 min read
